Soporte circulatorio mecánico escalonado en TIH pediátrica: anticoagulación con bivalirudina a través de ECMO, VAD y trasplante cardíaco

IntroductionHeparin induced thrombocytopenia (HIT) with in paediatric population is rare and subsequent anticoagulation management is challenging. Bivalirudin is a viable alternative to heparin for anticoagulating paediatric patients with HIT, though clinical data are limited. We describe the successful management of anticoagulation with bivalirudin from diagnosis through Extracorporeal Membrane Oxygenation (ECMO), Ventricular Assist Device (VAD) implantation, and heart transplantation in a child with dilated cardiomyopathy and HIT.MethodsA 14-year-old girl presented with acute heart failure, intracardiac thrombi, and adenovirus positivity. Heparin was exchanged for bivalirudin once HIT criteria were met, associated with thrombocytopenia and progressive thrombus formation within the right atrium and superior vena cava (SVC). Due to end-organ dysfunction and refractory cardiac failure veno-arterial ECMO was initiated. Failure to achieve sufficient recovery prompted a VAD implantation, and subsequent orthotopic heart transplantation both managed using a modified bivalirudin protocol.ResultsManaging ECMO in the presence of HIT and intracardiac thrombi required careful multidisciplinary planning. We adjusted the bivalirudin infusion from 0.35 to 1.9 mg/kg/hr to maintain an activated Partial Thromboplastin Time (aPTT) of 60-90 s, following our institutional protocol. For VAD implantation, we used citrate for circuit priming and initiated cardiopulmonary bypass without heparin, administering six bivalirudin boluses and escalating the infusion from 1.62 to 10 mg/kg/hr to achieve an Activated Clotting Time (ACT) > 400 s, with continuous ACT monitoring. During transplantation, anticoagulation involved four boluses and increasing the infusion from 0.35 to 5 mg/kg/hr to maintain an ACT >400 s. Despite significant post-CPB coagulopathy, which required delayed chest closure to control bleeding, no thrombotic events occurred. The bivalirudin protocols allowed safe progression through all three phases.ConclusionBivalirudin strategy provided safe, effective antithrombotic management across ECMO, VAD implantation, and heart transplantation in a paediatric patient with HIT. Monitoring its effectiveness at higher anticoagulation levels remains challenging, and patients may require higher doses to achieve desired endpoints.

Resumen tomado de PubMed (NCBI) para el registro citado, en el idioma original. La versión de referencia es la de la publicación original.

El resumen se deja sin traducir para conservar la redacción original de los autores.

Se describe una niña de 14 años con miocardiopatía dilatada y trombocitopenia inducida por heparina (TIH), manejada con bivalirudina tras suspender la heparina, durante ECMO, VAD y trasplante ortotópico. Durante la ECMO la bivalirudina se tituló entre 0,35 y 1,9 mg/kg/h (objetivo TTPa 60–90 s). Para el VAD se realizó una CEC sin heparina, cebado con citrato y dosis escalonada hasta 10 mg/kg/h (TCA >400 s). Los autores concluyen que la bivalirudina permitió una anticoagulación segura en las tres fases.

Explore cómo esta investigación se conecta con la práctica clínica

Más estudios revisados por pares en la categoría «Desarrollo de fármacos».

• Hirudoterapia en medicina y odontología — Jha K et al. (2015)
• Terapia con sanguijuelas: una historia — Hyson J (2005)
• Hirudinas de la sanguijuela medicinal asiática Hirudinaria manillensis: iguales, pero diferentes — Lukas P et al. (2019)
• Transcriptomic analysis of the salivary gland of medicinal leech Hirudo nipponia — Lu Z et al. (2018)
• Molecular dynamic and pharmacological studies on protein-engineered hirudin variants of Hirudinaria manillensis and Hirudo medicinalis — Sun Y et al. (2022)
• Síntesis acelular de la variante 1 de hirudina de la sanguijuela hematófaga Hirudo medicinalis — Wüstenhagen D et al. (2020)
• Producción de variantes de hirudina mediante fábricas microbianas modificadas genéticamente — Zhang J, Lan N (2018)
• Hirudina en la trombocitopenia inducida por heparina — Lubenow N, Greinacher A (2002)
• La hirudina mejora la nefropatía diabética al inhibir la piroptosis mediada por Gsdmd — Han J et al. (2023)
• La hirudina como anticoagulante alternativo: una revisión histórica — Markwardt F (2002)

Ver toda la investigación analizada por la ASH →